FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental pharmacology and urology, and concerns prevention of renal dysfunction in experiment. That is ensured by introducing carbamylated darbepoetin in dose of 50 mcg/kg subcutaneously into a wit area in white labs 24 hours prior to modeling the renal pathology by applying non-traumatic clamps onto the renal pedicles for 40 minutes, followed by reperfusion of blood flow in the kidneys.
EFFECT: administering the preparation at an experimentally set time in the declared dose provides effective prevention of renal ischemia reperfusion disorders.
1 cl, 1 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING RENAL ISCHEMIA REPERFUSION INJURY BY CARBAMYLATED DARBEPOETIN IN EXPERIMENT | 2018 |
|
RU2678768C1 |
METHOD FOR PREVENTING RENAL DYSFUNCTION WITH AN ARGINASE II INHIBITOR IN EXPERIMENT | 2018 |
|
RU2696580C1 |
METHOD FOR PREVENTING ISCHEMIA-REPERFUSION RENAL INJURIES WITH AN INHIBITOR OF ARGINASE II IN EXPERIMENT | 2018 |
|
RU2695333C1 |
METHOD FOR PREVENTING MICROCIRCULATION DISORDERS IN KIDNEYS WITH ASIALISED ERYTHROPOIETIN IN EXPERIMENT | 2018 |
|
RU2696864C1 |
METHOD FOR CORRECTING MICROCIRCULATION DISORDERS IN KIDNEY WITH INFLIXIMAB IN ISCHEMIA-REPERFUSION INJURY | 2021 |
|
RU2753247C1 |
METHOD FOR CORRECTING MICROCIRCULATION DISORDERS IN KIDNEY WITH PEPTIDE THAT MIMICS ALPHA-HELIX B OF ERYTHROPOIETIN IN ISCHEMIA-REPERFUSION INJURY | 2021 |
|
RU2751413C1 |
METHOD OF AGENT APPLICATION BASED ON HUMAN MODIFIED PEROXYREDOXIN 2 FOR CORRECTING CONSEQUENCES OF ISCHEMIC-REPERFUSIVE KIDNEY DAMAGE | 2020 |
|
RU2747121C1 |
METHOD FOR PREVENTING AND TREATING ACUTE POSTISCHEMIC RENAL INSUFFICIENCY | 2020 |
|
RU2737802C2 |
METHOD OF KIDNEY PREUNCONDITIONING IN CARDIOVASCULAR SURGERY | 2019 |
|
RU2712015C1 |
AGENT, USE THEREOF AND A METHOD OF INCREASING RESISTANCE OF A MAMMALIAN ORGANISM TO ISCHEMIC-REPERFUSION INVOLVEMENT OF THE SMALL INTESTINE | 2018 |
|
RU2729788C2 |
Authors
Dates
2019-07-23—Published
2018-09-25—Filed